PharmaFocus Today – Page 12 – media

Haogrei Secures Tens of Millions of Yuan in Strategic Financing; Domestic Liquid Metal Bearing X ray Tubes Deployed in Multiple Class III A Hospitals

Recently, Haogrei Technology, an innovator focusing on core components for high end medical imaging, announced the completion of tens of millions of yuan in strategic financing. The round was jointly invested by Anhui Tongchuang Small and Medium sized Sci Tech Transformation Fund Partnership (L.P.), Shenzhen Tongchuang Angel Phase II Private Equity Venture Capital Fund Partnership (L.P.), Huzhou Nanhui Xunying Venture Capital Partnership (L.P.), and Huzhou Nanxun Xunying Venture Capital Partnership (L.P.). The proceeds will be used for large scale mass production and capacity expansion of core products, R&D investment in next generation technology platforms, recruitment of key talents, and construction of global marketing channels. Previously, Haogrei Technology had secured support from multiple leading institutions including Tongchuang Weiye, Yuanming Capital, and Su Venture Capital, with cumulative financing reaching nearly 100 million yuan. This fully demonstrates capital market confidence in its technical strength and the prospects of domestic substitution for core components ...
- Source: drugdu
- 94
- April 9, 2026
With revenue surging 7.6 times, another innovative pharmaceutical company delivers outstanding results.

Recently, Wangshan Wangshui released its first financial report since its listing on the Hong Kong Stock Exchange. In 2025, the company’s annual revenue reached RMB 102 million, a year-on-year increase of 762.9% , and the gross profit margin soared from 29.5% to 79.0%. The explosive growth in revenue was mainly due to the rapid increase in sales volume after the launch of the new ED drug and the revenue from licensing new indications for VV116. However, Wangshan Wangshui’s losses widened further to 360 million yuan in 2025, mainly due to share-based payment expenses and listing-related costs. Excluding these one-off factors, the company’s core business’s ability to generate cash is strengthening . 01 The commercialization of the new ED drug got off to a flying start. In 2025, the biggest highlight of Wangshan Wangshui will be the successful NMPA approval of the Class 1 new drug Onveda (seminafil hydrochloride tablets, R&D ...
- Source: drugdu
- 96
- April 8, 2026
$53.7 billion! Lilly’s new betting direction

When Eli Lilly acquired Centessa Pharmaceuticals for $7.8 billion (approximately RMB 53.7 billion), the market saw not only a high-premium deal, but also a strategic positioning for the future of neuroscience. While pharmaceutical giants are betting heavily on popular areas such as weight loss and oncology, why is Eli Lilly going against the grain and investing heavily in “wake-up” drugs? 01 Acquisition at a 41% premium In mergers and acquisitions in the biopharmaceutical industry, the premium often directly reflects the acquirer’s judgment on the value of the target asset. Eli Lilly’s 40.5% premium and the transaction structure of $6.3 billion down payment + $1.5 billion CVR are by no means blindly following the trend, but are based on a deep recognition of Centessa’s core asset – the OX2R agonist combination. From the transaction structure perspective, Eli Lilly’s payment method reflects both its affirmation of Centessa’s existing assets and its avoidance ...
- Source: drugdu
- 94
- April 8, 2026
[Another Achievement] Hengdao Pharmaceuticals’ Peramivir Sodium Chloride Injection Approved for Marketing

Innovation and progress, perseverance and a commitment to excellence – another achievement! Recently, our company’s Class 4 chemical drug, Peramivir Sodium Chloride Injection, received a Drug Registration Certificate issued by the National Medical Products Administration. This is considered equivalent to passing the consistency evaluation of generic drug quality and efficacy, further authoritative recognition of our R&D capabilities. Details are as follows: Basic information about drugs Generic name of the drug: Peramivir Sodium Chloride Injection English name: Peramivir and Sodium Chloride Injection Dosage form: Injection Specifications: 100ml: Peramivir (calculated as C 15 H 28 N 4 O 4 ) 0.15g and Sodium Chloride 0.9g Registration Category: Class 4 Chemical Drugs Listing Authorization Holder: Nanjing Hengdao Pharmaceutical Technology Co., Ltd. Drug Approval Number: National Drug Approval Number H20263763 Indications: Used for influenza A or B. For the treatment of influenza A and B (peramivir is effective in treating influenza A and B, ...
- Source: drugdu
- 86
- April 8, 2026
Good news! Chang Le Pharmaceutical’s Bumetanide Injection has received approval for its Supplemental Drug Application

Recently, Chang Le Pharmaceutical, a subsidiary of Lianhuan Pharmaceutical, received the “Approval Notice for Supplementary Drug Application” issued by the National Medical Products Administration. Bumetanide injection was successfully approved, marking a new stage in the company’s production and supply capacity and quality management level in the field of diuretics, and injecting strong momentum into the company’s high-quality development. Bumetanide injection is a commonly used, potent diuretic in clinical practice, widely applied in the treatment of edematous diseases, hypertension, prevention of acute renal failure, and hyperkalemia, demonstrating significant clinical value. This approval includes a new 1ml:0.5mg product specification, along with simultaneous changes to the manufacturing process, production volume, and packaging materials and containers. Since the project’s inception, Chang Le Pharmaceutical has assembled a professional R&D and production team, conducting systematic pharmaceutical research over several months. Adhering strictly to national drug development principles, the team has carried out comprehensive and in-depth experimental ...
- Source: drugdu
- 84
- April 8, 2026
New Drug Launch | Gan & Lee Pharmaceuticals’ Sitagliptin Metformin Tablets (II) Approved

Beijing, China, April 7, 2026 – Gan & Lee Pharmaceuticals Inc. (hereinafter referred to as “Gan & Lee Pharmaceuticals”, stock code: 603087.SH) announced that its wholly-owned subsidiary, Gan & Lee Pharmaceuticals Shandong Co., Ltd., recently received a drug registration certificate for sitagliptin metformin tablets (II) issued by the National Medical Products Administration (hereinafter referred to as “NMPA”) (Acceptance No.: CYHS2403373, Certificate No.: 2026S00914, Drug Approval No.: H20263765). Sitagliptin and metformin tablets (II) are a combination oral hypoglycemic agent. Each tablet contains 50 mg of sitagliptin phosphate (calculated as sitagliptin) and 850 mg of metformin hydrochloride. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that stimulates insulin release in a glucose-dependent manner and reduces glucagon levels by increasing the level of active incretin. Metformin inhibits hepatic gluconeogenesis, reduces glucose absorption in the small intestine, and improves peripheral tissue sensitivity to insulin by increasing glucose uptake and utilization. This product, in combination with ...
- Source: drugdu
- 85
- April 8, 2026
$400 Million! AI Unicorn Anthropic Acquires Coefficient Bio

On April 7, according to The Information and Eric Newcomer, AI giant Anthropic is continuing its push into healthcare with the acquisition of Coefficient Bio, a previously little-known AI biotechnology startup, in a $400 million stock deal. The acquisition was confirmed by people familiar with the matter, and Coefficient’s PitchBook page also reflects the $400 million transaction.In early April, Anthropic, the U.S. AI unicorn, announced the completion of a $30 billion Series G funding round, valuing the company at $380 billion—a sharp increase from its $183 billion valuation in the previous Series F round. In less than three years since its founding, it has achieved $14 billion in annualized revenue, with growth of more than 10-fold each year over the past three years. Aris Theologis is CEO and co-founder of Coefficient. He previously served as Chief Business Officer of Evozyne and Vice President of Paragon Biosciences. He also has extensive ...
- Source: drugdu
- 74
- April 8, 2026
Sinovac Biotech and Changzhou Pharmaceutical Factory have reached a strategic cooperation agreement and signed an exclusive licensing agreement for two cardiovascular drugs in overseas markets.

Recently, Sinovac BiotechSinovac Biotech Co., Ltd. (hereinafter referred to as ” Sinovac Biotech”)(Stock code 688136.SH) and Shanghai PharmaceuticalsChangzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as “Changzhou Pharmaceutical Factory”), a subsidiary of the Group, held a strategic cooperation signing ceremony and an exclusive licensing agreement for two products, ticagrelor tablets and rosuvastatin calcium tablets, in several European countries. Leveraging Sinovac Biotech ‘s mature overseas commercialization network and Changzhou Pharmaceutical Factory’s high-quality product R&D and manufacturing capabilities, the two parties will join hands to expand into the European market, bringing domestically produced cardiovascular drugs to more patients. Enriching the European product line and continuously cultivating the major market It is understood that both products launched through this collaboration have been approved in China and the United States and are currently undergoing registration applications in several European countries. The cooperation covers markets including Germany, Spain, the Netherlands, Italy, and France. Ticagrelor tablets ...
- Source: drugdu
- 225
- March 31, 2026
Bayer’s fenelitonee has been approved in the European Union for use in adult patients with heart failure with LVEF ≥ 40%.

Based on the positive results of the Phase III FINEARTS-HF study, the European Union approved fenelone for patients with heart failure with a left ventricular ejection fraction (LVEF) ≥40%. The study included approximately 6,000 patients with various types and conditions of heart failure with LVEF ≥40%. Fennellone is the first mineralocorticoid receptor antagonist to demonstrate definite cardiovascular benefits in a phase III clinical trial in patients with heart failure and LVEF ≥ 40%. More than 15 million people in Europe suffer from heart failure, of whom about 50% have an LVEF ≥ 40%. Currently, there are limited approved treatment options for this group that meet guideline recommendations, and the risk of cardiovascular events remains high. On March 30, 2026, Bayer announced that the European Commission approved the selective nonsteroidal mineralocorticoid receptor antagonist fenelazor (Cosminda®) for the treatment of adult patients with heart failure with a left ventricular ejection fraction (LVEF) ...
- Source: drugdu
- 123
- March 31, 2026
World’s first! Amgen/AstraZeneca’s blockbuster drug approved for marketing in China

On March 27, the NMPA website showed that terzafimumab injection, a TSLP monoclonal antibody jointly submitted by AstraZeneca and Amgen , was approved for marketing. The drug was approved for two indications: asthma (application number: JXSS2400102/3) and chronic sinusitis with nasal polyps (application number: JXSS2500019/20) . Screenshot source: NMPA official websiteTezaliumab, developed in collaboration between AstraZeneca and Amgen, is a first-in-class human monoclonal antibody that inhibits the action of TSLP. TSLP is a key epithelial cytokine located at the top of multiple inflammatory cascades and is closely associated with allergic, eosinophilic, and other types of endothelial inflammation related to severe asthma and other inflammatory diseases.In 2021, the drug was first approved by the FDA for adjunctive maintenance therapy in adults and children aged 12 years and older with severe asthma . In 2022, it was approved in the European Union and Japan. In October 2025, the drug was approved for a new indication in the United States for maintenance therapy of poorly controlled chronic sinusitis with ...
- Source: drugdu
- 134
- March 31, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.